He has been a vital part of Umeå Biotech Incubator (UBI) since its inception in 2003. But now, after 42 years of service in the biotech industry, it is time for respected research engineer Assar Bäckman to retire.
“My work has been hugely varied, and over the years I have learned a great deal. I usually have an emergency solution to most things if needed”, says Assar.
Umeå-based biopharmaceutical company Omnio AB, which is currently awaiting efficacy data from preclinical wound studies using recombinant plasminogen, has recently appointed an internationally experienced board of directors charged with taking the company forward.
“Our new board’s network and experience will allow us to build strategic partnerships with pharmaceutical and biotechnology companies, accelerate our clinical development program and ultimately bring our wound-healing candidate to market”, says Ulrika Norin, CEO of Omnio.
The drug could mean a global treatment revolution for wounds that never heal. Now, the Umeå-based biopharmaceutical company Omnio AB has received a capital injection of 1.5 million euros from its shareholders, which will be used for ongoing development work and to begin creating a blueprint for manufacturing.
Umeå-based biopharmaceutical company Omnio has appointed Ulrika Norin, who has a long history of working with drug development startups, as its new CEO.
“I am excited look forward to being a part of Omnio’s team. We have made significant progress in finding identifying ways to help difficulthard-to-treat heal patients with their chronic wounds. Our work feels rewarding and important”, says Ulrika Norin.
Swedish life science company Omnio has received millions in funding from the Swelife innovation programme to help develop a cure for tooth loss.
“Thanks to these funds from Swelife we can now move forward even faster”, says Omnio’s CEO Patric Stafshede.
